Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers.

Abstract

BACKGROUND:

Vaccine-induced population immunity is a key global strategy to control coronavirus disease 2019 (COVID-19). The rapid implementation and availability of several COVID-19 vaccines is now a global health-care priority but more information about humoral responses to single- and double-dose vaccine is needed.

METHODS:

163 health care workers (HCW) of the Padua University Hospitals, who underwent a complete vaccination campaign with BNT162b2 vaccine were asked to collect serum samples at 12 (t12) and 28 (t28) days after the first inoculum to allow the measurement of SARS-CoV-2 Antibodies (Ab) using chemiluminescent assays against the spike (S) protein and the Receptor Binding Domain (RBD) of the virus, respectively.

RESULTS:

Significant differences were found at t12 for infection-naïve and subjects with previous-natural infection who present higher values of specific antibodies, while no significant differences have been found between t12 and t28. No statistically significant difference was found between male and female, while lower Ab levels have been observed in subjects older than 60 years at t12 but not at t28.

CONCLUSIONS:

Our study confirms observed differences in vaccine responses between infection-naïve and subjects with previous natural infection at t12 but not for a longer time. The influence of sex and age deserves further studies, even if the relationship with age seems particularly significant.

• Authors: Andrea Padoan, Luigi Dall'Olmo, Foscarina Della Rocca, Francesco Barbaro, Chiara Cosma, Daniela Basso, Annamaria Cattelan, Vito Cianci, Mario Plebani
• Journal: Clinica chimica acta; international journal of clinical chemistry (Clin Chim Acta) Vol. 519 Pg. 60-63 (Aug 2021) ISSN: 1873-3492 [Electronic] Netherlands
• PMID: 33857476 (Publication Type: Journal Article)
• Copyright: Copyright © 2021 Elsevier B.V. All rights reserved.

Chemical References

• COVID-19 Vaccines
• BNT162 Vaccine

Topics

• Antibody Formation
• BNT162 Vaccine
• COVID-19
• COVID-19 Vaccines
• Female
• Health Personnel
• Humans
• Male
• SARS-CoV-2